TGF-β1 Cancer Research Results

TGF-β1, Transforming Growth Factor-Beta 1: Click to Expand ⟱
Source:
Type:
TGF-β1 is one of three TGF-β ligands (β1, β2, β3) that initiate the TGF-β signaling cascade.
In the context of cancer, TGF-β1 plays a dual role:
Tumor Suppressor in Early Stages: In normal and early-stage tumor cells, TGF-β1 typically inhibits cell proliferation, induces apoptosis, and maintains tissue homeostasis.
Tumor Promoter in Advanced Stages: As cancer progresses, TGF-β1 often promotes epithelial-to-mesenchymal transition (EMT), enhances invasiveness, contributes to immune evasion, and fosters a pro-metastatic microenvironment.

Role in Early Tumorigenesis: Acts as a tumor suppressor via growth arrest and apoptosis.
Role in Advanced Cancers: Promotes EMT, invasion, metastasis, and immune suppression.
Expression in Cancer Types: Increased in advanced/ aggressive tumors in many cancer types.
Prognostic Implications Elevated TGF-β1: associated with poor prognosis in several cancers due to its pro-tumorigenic functions.
Therapeutic Targeting Blocking TGF-β1 activity (via antibodies or ligand traps) to reduce its tumor-promoting actions.
Scientific Papers found: Click to Expand⟱
5444- AG,    A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine
- Review, Var, NA
*Imm↑, *antiOx↑, *Inflam↓, AntiTum↑, eff↑, chemoP↑, Dose↝, TumCMig↓, TumCP↓, Akt↓, GSK‐3β↓, MMP2↓, MMP9↓, EMT↓, PI3K↓, Akt↓, NF-kB↓, Inflam↓, TGF-β1↓, TNF-α↓, IL6↓, Fas↓, FasL↓, NOTCH1↓, JNK↓, TumCG↓,
2694- BBR,    Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells
- in-vitro, BC, NA
IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,
7046- GA,    Gallic acid: A promising anti-non-small cell lung cancer compound targeting early growth response protein-1 for apoptosis and ferroptosis
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, Ferroptosis↑, THBS1↓, EGR1↓, TGF-β1↓, SMAD2↓, SMAD3↓, GPx4↓, ROS↑, i-MDA↑, i-Iron↑,
8007- JG,    Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis
- in-vitro, GBM, U251
Pin1↓, AntiCan↑, TumCP↓, Apoptosis↑, Casp3↑, TumCMig↓, angioG↓, VEGF↓, CD31/PECAM-1↓, TGF-β1↓,
8378- LT,    Luteolin and its derivatives: modulation of epithelial-mesenchymal transition in fibrosis and cancer
- Review, Var, NA
EMT↓, TGF-β1↓, Smad1↓, PI3K↓, Akt↓, Hippo↝, YAP/TEAD↓, *NRF2↑, *HO-1↑, *ROS↓, E-cadherin↑, ZO-1↑, Vim↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, TCF↓, Zeb1↓, angioG↓, eff↑, ROS↑, mtDam↑, MMP↓, ETC↓,
4926- PEITC,    PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT
- in-vitro, CRC, SW48
TumCI↓, TumCMig↓, EMT↓, Smad1↓, AntiCan↑, Snail↓, Slug↓, Zeb1↓, ZEB2↓, TGF-β1↓, eff↑, E-cadherin↑, N-cadherin↓, Vim↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   i-Iron↑, 1,   i-MDA↑, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ETC↓, 1,   MEK↓, 1,   MMP↓, 1,   mtDam↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   Apoptosis↑, 2,   Casp3↑, 1,   Fas↓, 1,   FasL↓, 1,   Ferroptosis↑, 1,   Hippo↝, 1,   JNK↓, 1,   YAP/TEAD↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 3,   ERK↓, 1,   GSK‐3β↓, 1,   NOTCH1↓, 1,   PI3K↓, 2,   TCF↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

CD31/PECAM-1↓, 1,   CLDN1↓, 1,   E-cadherin↑, 2,   MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   Slug↓, 1,   Smad1↓, 2,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 2,   TGF-β1↓, 6,   THBS1↓, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 3,   Vim↓, 2,   Zeb1↓, 2,   ZEB2↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 1,   EGR1↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   chemoP↑, 1,   Pin1↓, 1,  
Total Targets: 64

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,   Inflam↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: TGF-β1, Transforming Growth Factor-Beta 1
1 Astragalus
1 Berberine
1 Gallic acid
1 Juglone
1 Luteolin
1 Phenethyl isothiocyanate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1099  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page